Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 517,927Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Mekinist

02 11Tafinlar/Mekinist

PharmaCompass

01

Brand Name : Tafinlar/Mekinist

Dabrafenib, Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Dabrafenib, Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,542

2019 Revenue in Millions : 1,338

Growth (%) : 15

blank

02

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,542

2019 Revenue in Millions : 1,338

Growth (%) : 15

blank

03

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 1,693

2020 Revenue in Millions : 1,542

Growth (%) : 10

blank

04

Brand Name : Tafinlar/Mekinist

Dabrafenib, Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Dabrafenib, Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 1,693

2020 Revenue in Millions : 1,542

Growth (%) : 10

blank

05

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,770

2021 Revenue in Millions : 1,693

Growth (%) : 5

blank

06

Brand Name : Tafinlar/Mekinist

Dabrafenib, Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Dabrafenib, Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,770

2021 Revenue in Millions : 1,693

Growth (%) : 5

blank

07

Brand Name : Tafinlar/Mekinist

Dabrafenib, Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Dabrafenib, Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,922

2022 Revenue in Millions : 1,770

Growth (%) : 9

blank

08

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,922

2022 Revenue in Millions : 1,770

Growth (%) : 9

blank

09

Brand Name : Tafinlar/Mekinist

Dabrafenib, Trametinib

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
ChemOutsourcing
Not Confirmed

Dabrafenib, Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 2,058

2023 Revenue in Millions : 1,922

Growth (%) : 7

blank

10

Brand Name : Mekinist

Trametinib

arrow
ChemOutsourcing
Not Confirmed